Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

Journal:

Nature Medicine

Published:

2026-03-25

DOI:

10.1038/s41591-026-04299-5

Affiliations:

20

Authors:

66

Go to article

Institutions	Authors	Share
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	57.600000 57.600000 57.600000 57.600000 57.600000 57.600000	0.87
Weill Cornell Medicine, United States of America (USA)	7.283333	0.11
Parker Institute for Cancer Immunotherapy, United States of America (USA)	0.450000	0.01
Harvard Medical School (HMS), United States of America (USA)	0.333333	0.01
Curie Institute, France	0.333333	0.01
Howard Hughes Medical Institute (HHMI), United States of America (USA)	0.000000	0.00

Interested in Oncology and Carcinogenesis?